| 主权项 |
1. A method for preventing or treating a neuroinflammatory, an autoimmune disease, or a lipid storage disease in a subject, comprising administering to a subject an effective amount of one or more ribonucleotide reductase inhibitors, or a pharmaceutically acceptable salt thereof, having the formula:wherein the index n is 0 or 1;X is N or CR;R is chosen from hydrogen and hydroxyl;Y is a unit having the formula:R4 is chosen from:
i) O; ii) S; or iii) NR7: R7 is chosen from: i) hydrogen; ii) hydroxy; iii) amino iv) cyano; v) substituted or unsubstituted C1-C4 linear or branched alkyl; vi) substituted or unsubstituted C1-C4 linear or branched alkoxy; or vii) NR8R9; R8 and R9 are each independently chosen from hydrogen, hydroxy, amino, C1-C4 linear or branched alkyl, C1-C4 linear or branched alkoxy, or C(═R10)R11; R10 is chosen from O, S, or NR12; R12 is hydrogen, hydroxyl, or amino; is chosen from hydrogen, hydroxyl, amino, cyano, C1-C4 linear or branched alkyl, or C1-C4 linear or branched alkoxy;R5 is chosen from:
i) hydrogen; ii) hydroxy; iii) cyano; iv) substituted or unsubstituted C1-C10 linear or branched alkyl; v) substituted or unsubstituted C1-C10 linear or branched alkoxy; vi) substituted or unsubstituted phenoxy; or vii) NR14; R13 and R14 are each independently chosen from hydrogen, hydroxy, amino, C1-C4 linear or branched alkyl, C1-C4 linear or branched alkoxy, or C(═R15)R16; R15 is chosen from O, S, or NR17; R17 is hydrogen, hydroxyl, or amino; R16 is chosen from hydrogen, hydroxyl, amino, cyano, C1-C4 linear or branched alkyl, or C1-C4 linear or branched alkoxy;R6a and R6b are each independently hydrogen, hydroxy, amino, C1-C4 linear or branched alkyl, or C1-C4 linear or branched alkoxy;the index x is 0 or 1;Z is chosen from:
i) hydrogen; ii) hydroxyl; iii) NR18aR18b; R18a and R18b are each independently chosen from hydrogen, hydroxy, amino, C1-C6 linear or branched alkyl, C1-C6 linear or branched alkoxy, or C(═R21)R22; R21 is chosen from O, S, or NR23; R23 is hydrogen, hydroxyl, or amino; R22 is chosen from hydrogen, hydroxyl, amino, cyano, C1-C6 linear or branched alkyl, or C1-C6 linear or branched alkoxy; iv) NR19NR20aR20b; R19, R20a, and R20b are each independently chosen from hydrogen, hydroxy, amino, C1-C6 linear or branched alkyl, C1-C6 linear or branched alkoxy, or C(═R21)R22; R21 is chosen from O, S, or NR23; R23 is hydrogen, hydroxyl, or amino; R22 is chosen from hydrogen, hydroxyl, amino, cyano, C1-C6 linear or branched alkyl, or C1-C6 linear or branched alkoxy; v) substituted or unsubstituted C1-C6 linear or branched alkyl; vi) substituted or unsubstituted C1-C6 linear or branched alkoxy; vii) —C(O)OR24; R24 is hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted phenyl; viii) —OC(O)R25; R25 is substituted or unsubstituted C1-C6 alkyl or substituted or unsubstituted phenyl; ix) substituted or unsubstituted C6 or C10 aryl; x) substituted or unsubstituted C1-C9 heterocyclic; xi) substituted or unsubstituted C1-C9 heteroaryl; andR1, R2, and R3 are each independently chosen from:
i) hydrogen; ii) hydroxyl; iii) amino; iv) halogen; v) substituted or unsubstituted C1-C3 alkyl; vi) substituted or unsubstituted C1-C3 alkoxy; vii) —C(O)OR26; R26 is hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted phenyl; viii) —OC(O)R27; R27 is substituted or unsubstituted C1-C6 alkyl or substituted or unsubstituted phenyl; ix) —NR28NR29R30; R28 is hydrogen or C1-C3 alkyl, R29 and R30 are each independently chosen from hydrogen or C1-C3 alkyl; or x) R1 and R2 can be taken together to form a substituted or unsubstituted 6-member aryl ring. |
